Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.42 |
| ▸ | ELANE | P08246 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSPO | P30536 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183879 | 0.81 | CYP1A2 (0.48) | ELANETSHRSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL297494 | 0.79 | CYP1A2 (0.51) | TSHRSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL295717 | 0.77 | GUSB (0.48) | ELANE | |
| SCHEMBL183759 | 0.76 | KMT2A (0.52) | GRM2TSHRSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL16239664 | 0.70 | ELANE (0.67) | ELANELMNAMAPTNPSR1 | |
| SCHEMBL3910814 | 0.70 | ELANE (0.58) | ELANETSHRSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL16885076 | 0.68 | GRM2 (0.39) | GRM2ELANESMN1; SMN2KMT2ALMNA | |
| SCHEMBL7978070 | 0.68 | AMY1A (0.47) | SMN1; SMN2KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL183703 | 0.68 | PTGES (0.39) | GRM2PDE10A | |
| SCHEMBL1623051 | 0.67 | DHPS (0.42) | LMNAMAPTPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828150-B1 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | VERTEX PHARMA (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-1828150-B1 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | VERTEX PHARMA (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2366696-A1 | Process for producing 4-aminoquinazolines | Vertex Pharmaceuticals Incorporated (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2366696-A1 | Process for producing 4-aminoquinazolines | Vertex Pharmaceuticals Incorporated (US) | 2011-09-21 | — | — | EP | disclosed |
| CN-101111487-A | Processes for producing 4-aminoquinazolines | VERTEX PHARMA (US) | 2008-01-23 | — | — | CN | disclosed |
| EP-1828150-A2 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | Vertex Pharmaceuticals Incorporated (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060166963-A1 | Processes for producing 4-aminoquinazolines | VERTEX PHARMACEUTICALS INCORPORATED | 2006-07-27 | — | — | US | disclosed |
| WO-2006066044-A2 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166963-A1 | Processes for producing 4-aminoquinazolines | CACNA1I, CACNA1G, CACNA1B | GRM2 2284/4885ELANE 4826/4885TSHR 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.